H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Catalyst Pharma (CPRX) today and set a price target of $6. The company’s shares opened today at $2.98.
Fein noted:
“Our price target of $6/share is based on an equally weighted composite of: (a) $6.62/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.57 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2018-2024 of $4.46/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.4% and a 45.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Catalyst Pharma has an analyst consensus of Strong Buy, with a price target consensus of $6.25, implying a 109.7% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $8 price target.
.
See today’s analyst top recommended stocks >>
Based on Catalyst Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.84 million. In comparison, last year the company had a GAAP net loss of $4.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder.
Read More on CPRX:
